Senzime AB (SEZI) - Total Assets
Based on the latest financial reports, Senzime AB (SEZI) holds total assets worth Skr350.01 Million SEK (≈ $37.67 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SEZI cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Senzime AB - Total Assets Trend (2005–2025)
This chart illustrates how Senzime AB's total assets have evolved over time, based on quarterly financial data. Check Senzime AB tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Senzime AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Senzime AB's total assets of Skr350.01 Million consist of 34.6% current assets and 65.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr73.97 Million | 20.0% |
| Accounts Receivable | Skr21.43 Million | 5.8% |
| Inventory | Skr25.17 Million | 6.8% |
| Property, Plant & Equipment | Skr18.31 Million | 5.0% |
| Intangible Assets | Skr122.95 Million | 33.3% |
| Goodwill | Skr96.05 Million | 26.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Senzime AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Senzime AB market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Senzime AB's current assets represent 34.6% of total assets in 2025, an increase from 0.0% in 2005.
- Cash Position: Cash and equivalents constituted 20.0% of total assets in 2025, up from 2.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 58.0% of total assets, an increase from 10.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 33.3% of total assets.
Senzime AB Competitors by Total Assets
Key competitors of Senzime AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
Senzime AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.76 | 3.43 | 13.27 |
| Quick Ratio | 2.92 | 2.55 | 12.68 |
| Cash Ratio | 0.00 | 1.82 | 11.61 |
| Working Capital | Skr77.60 Million | Skr82.90 Million | Skr124.91 Million |
Senzime AB - Advanced Valuation Insights
This section examines the relationship between Senzime AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.40 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -12.9% |
| Total Assets | Skr369.81 Million |
| Market Capitalization | $74.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Senzime AB's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Senzime AB's assets decreased by 12.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Senzime AB (2005–2025)
The table below shows the annual total assets of Senzime AB from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr369.81 Million ≈ $39.80 Million |
-12.89% |
| 2024-12-31 | Skr424.53 Million ≈ $45.69 Million |
-2.08% |
| 2023-12-31 | Skr433.54 Million ≈ $46.66 Million |
+34.36% |
| 2022-12-31 | Skr322.68 Million ≈ $34.73 Million |
+84.79% |
| 2021-12-31 | Skr174.62 Million ≈ $18.79 Million |
-32.55% |
| 2020-12-31 | Skr258.89 Million ≈ $27.86 Million |
+37.88% |
| 2019-12-31 | Skr187.76 Million ≈ $20.21 Million |
-4.77% |
| 2018-12-31 | Skr197.16 Million ≈ $21.22 Million |
+18.75% |
| 2017-12-31 | Skr166.03 Million ≈ $17.87 Million |
+6.22% |
| 2016-12-31 | Skr156.31 Million ≈ $16.82 Million |
+226.99% |
| 2015-12-31 | Skr47.80 Million ≈ $5.14 Million |
+3.21% |
| 2014-12-31 | Skr46.32 Million ≈ $4.98 Million |
+19.90% |
| 2013-12-31 | Skr38.63 Million ≈ $4.16 Million |
+16.24% |
| 2012-12-31 | Skr33.23 Million ≈ $3.58 Million |
+4.97% |
| 2011-12-31 | Skr31.66 Million ≈ $3.41 Million |
+22.12% |
| 2010-12-31 | Skr25.92 Million ≈ $2.79 Million |
+22.41% |
| 2009-12-31 | Skr21.18 Million ≈ $2.28 Million |
-8.56% |
| 2008-12-31 | Skr23.16 Million ≈ $2.49 Million |
+69.54% |
| 2007-12-31 | Skr13.66 Million ≈ $1.47 Million |
+26.84% |
| 2006-12-31 | Skr10.77 Million ≈ $1.16 Million |
+11.03% |
| 2005-12-31 | Skr9.70 Million ≈ $1.04 Million |
-- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more